Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy

AIDS

Volumn 18, Issue 16, 2004, Pages 2145-2151

  Sabin, Caroline A ^a   Smith, Colette J ^a   Gumley, Helen ^b   Murphy, Gabrielle ^b   Lampe, Fiona C ^a   Phillips, Andrew N ^a   Prinz, Beth ^b   Youle, Mike ^b   Johnson, Margaret A ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CD4 cell count; Late presenters; Resource use; Treatment response; Virological response

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAIN DISEASE; CANDIDIASIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DRUG RESPONSE; DRUG UPTAKE; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE; TOXOPLASMOSIS; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; WASTING SYNDROME;

EID: 7744227969     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411050-00006     Document Type: Article

References (27)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
4. DeHovitz JA, Kovacs A, Feldman JG, Anastos K, Young M, Cohen M, et al. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: a report from the Women's Interagency HIV Study. J Infect Dis 2000, 182:1527-1530.
5. Smith CJ, Sabin CA, Lampe FC, Kinloch-de-Loes S, Gumley H, Carroll A, et al. The potential for CD4 cell increase in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003, 17:963-969.
6. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999, 13:951-956.
7. Nunez M, Asencio R, Valencia ME, Leal M, Gonzalez-Lahoz J, Soriano V. Rates, causes and clinical implications of presenting with low CD4+ cell counts in the era of highly active antiretroviral therapy. AIDS Res Hum Retrovir 2003, 19:363-368.
8. Sabin CA, Madge S, Tyrer M, Lampe F, Youle M, Lipman M, et al. Why do some patients have a low CD4 cell count in the era of highly active antiretroviral therapy (HAART)? Seventh Annual Conference of the British HIV Association. Brighton. April 2001 [abstract P35].
9. Curtis H, Sabin CA, Johnson MA on behalf of the British HIV Association Clinical Audit Committee. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003, 4:11-17.
10. Barry SM, Lloyd-Owen SJ, Madge SJ, Cozzi-Lepri A, Evans AJ, Phillips AN, et al. The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Med 2002, 3:129-134.
11. Easterbrook PJ, Yu LM, Goetgherbeur E, Boag F, McLean K, Gazzard B. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic. AIDS 2000, 14:561-571.
12. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001, 2:276-313.
13. CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the monotherapy era. AIDS 2004, 18:51-58.
14. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003, 362:679-686.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560-2567.
16. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
17. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
18. Sabin CA, Lampe FC, Chaloner C, Madge SJ, Lipman MCI, Youle M, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003, 4:87-93.
19. Sullivan AK, Curtis H, Sabin CA, Johnson MA on behalf of BHIVA and the BHIVA Audit subcommittee. National review of newly diagnosed HIV infections. Br Med J, in press.
20. Chadborn T, Dingley S, Morgan D, Evans BG. CD4 cell counts in HIV-infected adults at HIV diagnosis in England and Wales, 1990 to 2001. Ninth Annual Conference of the British HIV Association. Manchester, April 2003 [abstract O28].
21. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 < 200 cells/μl) with HIV infection. HIV Med 2004, 5:93-98.
22. Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis: characteristics of individuals. Int J STD AIDS 2000, 11:503-508.
23. Castilla J, Sobrino P, de la Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS 2002, 16:1945-1951.
24. Palacio H, Li X, Wilson TE, Sacks H, Cohen MH, Richardson J, et al. Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation and naivety. AIDS 2004, 18:621-630.
25. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002, 16:75-83.
26. Poznansky MC, Coker R, Skinner C, Hill A, Bailey S, Whitaker L, et al. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Br Med J 1995, 311:156-158.
27. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA Study: an observational cohort. Lancet 2003, 362:22-29.